A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN).

Sun, Yan; Shi, Y.; Zhang, L.; Liu, X.; Zhou, Chun‐Gao; Wang, Dan; Li, Q.; Zhang, Shu‐Han; Qin, Songbing; Hu, Chengping; Zhang, Y.; Chen, J.; Song, Yanwen; Feng, J.; Cheng, Yun; Zhang, H.; Wu, Yi‐Long; Xu, Ning; Zhou, Juechu

doi:10.1200/jco.2011.29.15_suppl.7522

Cited by 16 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the ICOGEN clinical study, icotinib has a similar efficacy to gefitinib (12,13) in the re-treatment of advanced NSCLC and is associated with a significantly lower incidence of adverse events (8,14). Icotinib is currently the standard therapy for advanced NSCLC in China.…”

Section: Discussionmentioning

confidence: 99%

“…Icotinib, a novel EGFR-TKI, exerted a distinctly inhibitory effect on NSCLC in vivo and in vitro. A phase III clinical study (ICOGEN) demonstrated that icotinib exhibits high efficacy in the re-treatment of advanced NSCLC, compared with gefitinib (8). The efficacy of small-molecule TKIs has been shown to be associated with the EGFR mutation status.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the efficacy of icotinib in patients with non-small-cell lung cancer according to the type of epidermal growth factor receptor mutation

Zhang¹,

Wen²,

Zhuang³

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with preclinical and clinical activity in non-small-cell lung cancer (NSCLC). Exon 19 deletion and L858R point mutation are the most commonly encountered EGFR mutations in NSCLC, and they predict improved clinical outcomes following treatment with icotinib. The objective of this study was to evaluate the differential clinical efficacy of icotinib in patients with exon 19 deletion or L858R point mutation of the EGFR gene. A total of 104 patients with advanced NSCLC, who harbored exon 19 deletion or L858R point mutation of EGFR and were treated with icotinib, were enrolled in this study. The tumor response and progression-free survival were evaluated. There were no significant differences between patients with EGFR exon 19 deletion and those with L858R point mutation who received treatment with icotinib.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Comparison of the efficacy of icotinib in patients with non-small-cell lung cancer according to the type of epidermal growth factor receptor mutation

Zhang¹,

Wen²,

Zhuang³

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Icotinib and erlotinib share a common chemical backbone structure but differ in their side chains (2); nonetheless, their side-effect profiles are different (4,11). In the two reported patients with HFS induced by erlotinib, dose reduction was ineffective (7,9).…”

Section: Discussionmentioning

confidence: 99%

“…Icotinib hydrochloride is a new, small-molecule, selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) (1)(2)(3)(4). A large randomized head-to-head phase III clinical trial (ICOGEN) demonstrated that icotinib has a similar efficacy to gefitinib in previously treated non-small cell lung cancer (NSCLC), with less toxicity (4).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hand-foot syndrome in a patient with metastatic lung adenocarcinoma induced by high-dose icotinib: A case report and review of the literature

Zheng

Fang

2012

Oncology Letters

View full text Add to dashboard Cite

Abstract. Icotinib is a new oral epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI). The most frequent side-effects of icotinib include rash and diarrhea. Hand-foot syndrome (HFS) induced by EGFR-TKI is rare. The present study describes, for the first time, HFS induced by high-dose icotinib in a 65-year old female with metastatic lung adenocarcinoma. The patient developed HFS during the first week of icotinib treatment with characteristic clinical presentation. HFS regressed after icotinib dose-reduction was initiated. HFS may occur with icotinib, especially when administered in high doses.

show abstract

The regulatory role of APE1 in epithelial‐to‐mesenchymal transition and in determining EGFR‐TKI responsiveness in non‐small‐cell lung cancer

et al. 2018

View full text Add to dashboard Cite

BackgroundEpithelial‐to‐mesenchymal transition (EMT) plays a pivotal role in resistance to EGFR tyrosine kinase inhibitors (TKIs) in non‐small‐cell lung cancer (NSCLC). Our previous study revealed that in osteosarcoma, human apurinic/apyrimidinic endonuclease 1 (APE1) regulates transforming growth factor‐β (TGF‐β), an important player in EMT. We therefore hypothesized a link between APE1 and EGFR‐TKI responsiveness in NSCLC.MethodsThe protein levels of APE1 were analyzed in tumors of NSCLC patients receiving EGFR‐TKI treatment. The correlation between APE1 expression and progression‐free survival (PFS), overall survival (OS), or response rate were analyzed. The impact of APE1 on the response to EGFR‐TKIs was measured by exogenous manipulation of APE1 in EGFR‐TKI‐sensitive and EGFR‐TKI‐resistant cells.ResultsWe indicate that low expression of APE1 in tumors is associated with a significantly longer PFS (20.8 months vs 8.4 months, P = 0.008) and a preferential OS (39.0 months vs 17.0 months, P = 0.001), with no difference in initial response rate to EGFR‐TKIs. We observed that APE1 protein level was significantly increased in EGFR‐TKI‐resistant cells and was associated with downregulated E‐cadherin and upregulated vimentin. The EMT phenotype, as well as the levels of TGF‐β, was suppressed in APE1 knockdown HCC827/IR and PC‐9/ER cells, while the EMT phenotype was promoted in APE1‐overexpressed HCC827 and PC‐9 cells. Furthermore, a specific APE1 redox inhibitor (ie, E3330) effectively reversed the EMT phenotype and further sensitized the cells to EGFR‐TKIs.ConclusionThis study revealed a significant role of APE1 in EGFR‐TKI resistance via novel regulatory effects on the EMT phenotype in NSCLC.

show abstract

A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN).

Cited by 16 publications

References 0 publications

Comparison of the efficacy of icotinib in patients with non-small-cell lung cancer according to the type of epidermal growth factor receptor mutation

Comparison of the efficacy of icotinib in patients with non-small-cell lung cancer according to the type of epidermal growth factor receptor mutation

Hand-foot syndrome in a patient with metastatic lung adenocarcinoma induced by high-dose icotinib: A case report and review of the literature

The regulatory role of APE1 in epithelial‐to‐mesenchymal transition and in determining EGFR‐TKI responsiveness in non‐small‐cell lung cancer

Contact Info

Product

Resources

About